This segment focuses on the development, manufacturing, and commercialization of radiopharmaceuticals for the diagnosis, staging, and treatment of various cancers. Key products include PYLARIFY, a PSMA-targeted PET imaging agent used in prostate cancer. Research and development efforts are directed towards expanding the oncology pipeline with novel radiotherapeutics and diagnostics, including targeted alpha therapies and next-generation imaging agents. The segment leverages advanced radiochemistry and molecular targeting technologies to improve the precision and efficacy of cancer treatments, aiming to enhance patient outcomes and quality of life. Strategic collaborations and acquisitions further strengthen the company's position in the radiopharmaceutical oncology market, driving innovation and expanding access to cutting-edge therapies.

This segment is dedicated to developing and commercializing diagnostic imaging agents that provide clinicians with critical information for the early detection, diagnosis, and management of various diseases. Key products include DEFINITY, a microbubble ultrasound enhancing agent, and TechneLite, a technetium generator for nuclear medicine. Research and development activities focus on improving the sensitivity and specificity of diagnostic imaging, as well as expanding the application of existing products to new clinical areas. The segment utilizes advanced imaging technologies, including PET, SPECT, and ultrasound, to visualize and quantify disease processes at the molecular level. By providing clinicians with more accurate and timely diagnostic information, this segment aims to improve patient outcomes and reduce healthcare costs. Future opportunities include the development of AI-powered image analysis tools and personalized diagnostic strategies.